Stock Plays

[breakout_trader34]

(((((((($$$CAGR$$$)))))))
Full Court Press!!

[WiseTrader]

Stock Manipulation & Stock Promoters are NOT welcomed here!
Such poster(s) will be banned.

[card counter]

Wise Trade

Cannot pull trigger on any penny stock.

Miss you good ideas. Weak market

[bikeguy]

Still at 1 mill O/S?

[WiseTrader]

VTPI 0.03-0.0305 The next possible 5 bagger!! >>

As of July 5th Vital Products, Inc. had 98,838,900 Shares Outstanding .

On July 6th VTPI did 1 - 100 Reverse Split & As a result, The current Outstanding Shares were 988,389 as of July 6th 2009.

VTPI was taken down from 0.60 to 0.02!

VTPI has started a bottom reversal move on 9/28/09 and closed 0.03- 0.0305 up 39.53 % .

VTPI RECENT NEWS
http://ih.advfn.com/p.php?pid=nmona&cb=1254190679&article=39427242&symbol=NB%5EVTPI

VTPI CHART:

[chrylaser]

$BYSD jumped 32% yesterday on just 23K volume. BYSD really moves on low volume. CEO confirmed that the merger will be completed this week. An investor awareness campaign is widely anticipated. Today's price action confirms this, IMO. BYSD will be at a dollar next week, IMO.

BYSD's iHub board is active with ton of DD-check it out:

http://investorshub.advfn.com/boards/board.aspx?board_id=8584

PR regarding expected September merger announcement:

http://finance.yahoo.com/news/Bayside-Petroleum-Company-Inc-iw-214562990.html?x=0&.v=1

GLTA!

[seeclear]

CYSG..Tomorrow... and the next year...Boardmarked...SC.

[vantillian]

Boardmarked.

[Green Money 00]

keep an eye on EWRC and EFLN

both hearing news next week

[Lucky2]

Hi WiseT, quik check in and i am loving Qasp and PFMS can I say YEEEHAW!!!! also ONCP coming back today I see.

[WiseTrader]

In ICTY (PLAY)

[WiseTrader]

Hey 'Lucky2' I am rocking :)Hope you are doing well .

[learning as I go]

HMIT, bouncer.........

[Lucky2]

Hi Wisetrader! Stoppin by to say hello before the day gets busy! Hope everything is going Great for you!

[WiseTrader]

ARTI 0.0019 Artfest International, Inc. at the Forefront of the Multi-Billion Dollar RFID Technology Curve

Thursday, July 30 2009 8:33 AM, EST Market Wire "US Press Releases "
DALLAS, TX -- (MARKET WIRE) -- 07/30/09 -- Artfest International, Inc. (OTCBB: ARTI) is pleased to announce that the Company is at the forefront of the multi-billion dollar RFID technology curve, along with corporations such as Apple, by establishing the worldwide "gold standard" for the arts and sports collectibles industry through its own RFID solution. According to a report written by the research firm of IDTechEx out of Cambridge, Massachusetts , the RFID market will increase to $27.1 Billion in 2016, a tenfold increase from the RFID market size in 2006 (http://www.rfidupdate.com/articles/index.php?id=1040).

Art and collectibles that are embedded with Artfest International's RFID technology allows consumers and investors to connect to a database that displays the parameters of that particular collectible, where it was purchased, when it was purchased, and for what amount it was purchased. If it is a limited edition piece, it allows the consumer to see what number of the limited edition they purchased. The Company's RFID technology also allows artists or athletes are able to see how many pieces or items were produced and/or sold. The information on the RFID chip can be read either through an iPhone, PDA, and/or with Artfest's reader package. According to Nicholas Forrest , an art market analyst, ten to forty percent of artwork on the market is fakes.

Other corporations and industries are starting to develop solutions and services based on RFID technology. According to an article published on July 9, 2009 on TG Daily's website (www.tgdaily.com/content/view/43165/135/), "Apple has filed several patents this week which point the way towards improvements it hopes to bring to its run-away success, the iPhone. According to Apple Insider, the patents include an ID App which will figure out which objects are around you." The article also stated that "The ID patent is interesting -- it cites, as examples someone in an art museum looking at a piece of art which can pick up detailed information about a particular exhibit. The idea is that a portable device could provide a number of different data relating to an object, and get extra information. One method might be to include an RFID reader, a camera and an IR image capture device."

"Our RFID technology and software aims to keep all the players in the arts and collectibles industry honest and as the RFID technology is improved, we will be able to develop more services and solutions to stay at the forefront of our industry," stated Edward Vakser , CEO of Artfest International, Inc.

"In our endeavor to secure Intellectual Properties , and create shareholder value, we are filing for trademarks and patents for our technology," explained Angie Tassan , Artfest CMO.

About Artfest International, Inc.

Artfest International, Inc. brings together artists, investors, decorators, designers, private collectors and art galleries. Artfest International's corporate site is www.artfestinternational.com. Artfest's subsidiaries are Art Channel, Inc. (www.artchannel.tv), and Art Channel Galleries, Inc. (www.ArtChannelGalleries.com), offering the most exciting product and rewards program in the history of direct sales marketing.

Safe Harbor Statement -- This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual or future results may differ materially from those anticipated depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ARTI does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact: Investor Relations 407-389-5900

[learning as I go]

CBIS

[learning as I go]

CBIS....getting to be a monster

[learning as I go]

CBIS, more news....

Cannabis Science to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medicines in Treatment of H1N1 Swine Flu as AP Report Predicts Swine Flu Could Hit up to 40 Percent in the USA

SAN FRANCISCO, CA, Jul 27, 2009 (MARKETWIRE via COMTEX) -- Cannabis Science, Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to report that it is moving as fast as possible to assist in the fight against the threat of a deadly influenza pandemic. In conjunction with its recent re-organization, the Company has begun discussions with the FDA as its program moves forward to provide FDA approved solutions for several critical illnesses.
H1N1 Swine Flu:

According to the CDC (http://www.cdc.gov/flu/avian/) the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.

Cannabis Science H1N1 Swine Flu Formulation:

We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its cannabis extract lozenge with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.

Dr. Robert Melamede, Ph.D., Cannabis Science, Inc., President and CEO, believes there is enormous potential value for cannabinoids to naturally reduce excessive inflammatory immune responses, and the Cannabis Science lozenge formulation could reduce the mortality rate and allow infected individuals to develop a strong natural immunity upon recovery. Dr. Melamede is the former Chairman (ret) of the Biology Department at the University of Colorado (Colorado Springs.)

Dr. Melamede added, "Again, we recommend, based on sound scientific principles, that medical marijuana users should switch to edibles if they come down with an influenza infection. We believe that the irritation associated with the pulmonary route, when a person has an influenza infection, may lead to unnecessary deaths. In contrast, oral administration may prevent many deaths. We hope that due to the magnitude of this pandemic threat, that the FDA will fast track our proposal."

FDA's three rapid special drug release programs:

Fast Track, Accelerated Approval and Priority Review are approaches that are intended to make therapeutically important drugs available at an earlier time. They do not compromise the standards for the safety and effectiveness of the drugs that become available through this process. These revitalized FDA drug review approaches have yielded tangible results in bringing safe and effective drugs to patients with serious diseases more quickly. For example, since 1996, 68 drugs for cancer therapies have received priority review and approval. The FDA reviewed Gleevec, a treatment for chronic myeloid leukemia, in four months. Shortened review times have also brought promising treatments to patients with HIV/AIDS more quickly. Kaletra for the treatment of HIV/AIDS was reviewed and approved in 3.5 months. Pegasys, a combination product for the treatment of Hepatitis C, was approved for marketing in 4 months.

Fast Track, Accelerated Approval, and Priority Review have evolved over time. The FDA has been vigilant in assuring that reducing the time necessary for drug development has not compromised the safety and effectiveness of drugs for patients with serious diseases. The median time required to review a priority review drug was reduced from 13.9 months to 6.7 months.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.



Contact:

Cannabis Science, Inc.
Dr. Robert J. Melamede
President & CEO
Email Contact
www.cannabisscience.com

[stocksurgeon]

Looks like it! well heres another one for the board.. PVRE .27!! very cheap.. about to have an ascedning triangle breakout on the hourly if
we can get over .31.

[learning as I go]

yep, I like it around here, some good plays float thru here

[stocksurgeon]

GM learning!!!! this seems to be a nice board here..

[learning as I go]

CBIS another huge day so far

[WiseTrader]

CICS 0.0014 Carbonics Acquires Rights to Algae Bioreactor Technologies

Monday, July 27 2009 8:00 AM, EST Business Wire "US Press Releases "
NEW YORK --(BUSINESS WIRE)-- Carbonics Capital Corporation (OTC Bulletin Board: CICS) is pleased to announce that it has entered into an exclusive license with GreenShift Corporation (OTC Bulletin Board: GERS) for use of its algae bioreactor technologies in municipal and industrial applications excluding ethanol production.

GreenShift's patented and patent-pending bioreactor technologies rely on thermophillic cyanobacteria (among other organisms) to consume carbon dioxide emissions and to produce carbon-neutral products. The organisms use the available carbon dioxide in the emissions and water to grow and give off oxygen and water vapor. The organisms also absorb nitrogen oxide and sulfur dioxide. All photosynthetic organisms need a supply of carbon dioxide, light, a growth media and water with nutrients to live and grow. GreenShift's bioreactor technologies have the potential to reduce the costs and technical barriers to managing the flow resources into, through and out of the bioreactor in a compact and cost-efficient way as compared to other algae bioreactor technologies.

Carbonics' wholly-owned subsidiary, Sustainable Systems, Inc. , was awarded a $375,000 grant from the Montana Department of Commerce Research and Commercialization Technology program and is pursuing additional funding to apply toward this project to move this technology forward.

"While certain engineering hurdles must be overcome, we remain excited about this technology and its applications to manage carbon dioxide emissions while creating raw material for value added products," stated Dr. Paul Miller , president and chief executive officer. In addition, Dr. Miller stated, "Our development team's assessment of the algae production state of the art suggests that this is a practical closed system technology deployable on a large scale. What is unique about this technology is that we retain a high level of control of the environmental conditions within the system and we believe we can tailor the conditions for the production of biomass-derived chemicals and other products that can have commercial values greatly exceeding fuel."

David Winsness , GreenShift's Chief Technology Officer, added that " GreenShift is exclusively focused on the commercialization needs of its patent-pending extraction technologies. While we originally acquired our bioreactor technologies with a long-term goal of developing applications capable of integrating into corn ethanol plants, these technologies have many other applications. The Carbonics team has the ability to evaluate and develop those applications, and to manage the continued evolution of our bioreactor technologies."

Under the terms of the license agreement, Carbonics will pay GreenShift ten percent of the pre-tax net income derived from the use of the technology or derived from the sale, sublicense or lease of technology related equipment. In addition, while GreenShift shall retain ownership of all improvements that Carbonics may develop, and the right to use any such improvements in GreenShift's ethanol applications, Carbonics shall retain the right to use those improvements under the license agreement.

About Carbonics Capital Corporation

Carbonics Capital Corporation (OTCBB: CICS) was founded to facilitate decarbonization in ways that cost-effectively capitalize on the evolving carbon markets.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Carbonics Capital Corporation and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully, and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.



Source: Carbonics Capital Corporation

[Mark]

SGMG, one left at .0035 ask.

[WiseTrader]

SGMG 0.0035 -0.0040 up 191% !!!!

[WiseTrader]

OWVI 0.0014- 0.0015 could be a MONSTER PLAY!

[WiseTrader]

EEGI 0.0028- 0.0030 FORM 15- 12G

[WiseTrader]

DVME 0.0008- 0.0009

[learning as I go]

me too, glad ya got some, sure looks to be a fun roller coaster ride

[WiseTrader]

Picked up few shares fwiw,Looks good for $1.00+ !Huge potential!imo!!!

[learning as I go]

"Buy a share of IJJ Corp. and stake a claim on a $5B case
By Jeff Benjamin
April 5, 2009, 6:01 AM EST
Post a Comment Recommend (12)


If buying shares in order to bet on a company’s financial performance doesn’t provide enough of a kick, try buying shares to bet on the outcome of a lawsuit.
Investors who want to take such a risk may consider the initial public offering from VR Holdings Inc. of Linthicum, Md., which is expected soon.

As reported in InvestmentNews in November, VR Holdings is a private holding company whose sole asset is a 13-year-old lawsuit. The company is planning to merge with IJJ Corp. (IJJP.PK), a Capital Heights, Md.-based shell company that used to provide information technology services to federal, state and local governments.

The merger is seen as a more efficient alternative to going through the process of listing VR Holdings as an over-the-counter stock, which was the original plan.

The stock-for-stock deal, which could close this month, is designed to provide liquidity for more than 2,500 claimants, 2,000 of whom are over age 65 and are concerned they may not live to see the suit settled.

The lawsuit, which involves racketeering charges against a half dozen hedge funds and money managers, is still awaiting a court date.

Because so much still hangs in the balance, potential investors should approach this situation with their eyes wide open.

It was almost a year ago that the U.S. District Court for the Northern District of Illinois dismissed the case, based on the expiration of a four-year statute of limitations.

The claimants are challenging the dismissal.

According to the claimants, the lawsuit issue boils down to how and why a six-month $23 million bridge loan made in 1996 by some of the money management firm defendants was allowed to lapse, giving lenders an 80% ownership stake in the company.

Morton Lapides, a 79-year-old plaintiff in the case, said his company, MML Inc. of Baltimore, was brought down in the “domino effect” of the failure of all four of its subsidiaries through the financing structure.

Mr. Lapides, a cancer patient, is participating in the two-pronged charge to get the case before a judge and provide some liquidity for the claimants.

The merger deal is expected to create approximately 550 million shares, which breaks down to about one share for every $13.50 worth of lawsuit claim.

The shares — which will be issued to claimants, minus a 50-million share dilution to accommodate the merger — will start trading in the range of $1 or less.

“We’re taking a 10% dilution to save the time and money of going through the whole filing process,” said Mr. Lapides. “IJJ Corp. will increase their authorized shares, and they will offer us one share for every share we would have outstanding.”

Quirky as it might seem, the general structure is not without some precedent.

As Mr. Lapides pointed out, during the savings and loan crisis 20 years ago, there were a few thrifts that folded lawsuit claims into their equity offerings.

But this is believed to be the first time a company’s sole asset is identified as a legal settlement.

For investors, the appeal is expected to be the potential return from a successful lawsuit or settlement.

Based on the projected total size of the lawsuit and $1 initial trading range of the shares, the ultimate return could exceed 1,200% — or it could be considerably less.

It is almost impossible to determine at this point when that final payout would likely arrive or what it might ultimately look like.

But assuming the claimants do get their desired level of liquidity, there is always the chance that the shares could eventually trade almost like futures contracts in which the price would fluctuate based on new information related to the projected outcome of the lawsuit.
http://www.investmentnews.com/article/20090405/REG/904039943

[learning as I go]

Wise, have you checked out IJJP yet?

[WiseTrader]

TXMC gapping 0.0029- 0.0030 Huge News yesterday!

Common Shares Outstanding:
887,172,007 as of February 4, 2009

According to the 20.8 million deal ,this could be 0.02-0.03 play in short term !!JMHO


WESTPORT, Conn. --(BUSINESS WIRE)-- The Tirex Corporation (OTCBB:TXMC) today announced that Simpro S.p.A. of Torino, Italy recently signed an approximate $20.8 million Memorandum of Understanding with Enchantex Solutions of Malaysia to manufacture, deliver, commission and warrant a turnkey tire recycling facility utilizing Tirex's patented, state of the art, tire recycling technology, the TCS System.

"This is a major milestone for Tirex and our TCS technology as it begins the production of the first commercial tire recycling system to freeze tire rubber with cold air as opposed to using expensive liquid nitrogen," according to Tirex's CEO John L. Threshie Jr.

"The completion of the TCS purchase agreement(s) will allow us to offer reduced price points of its higher value-added crumb rubber ideally suited as infill in the expanding and lucrative synthetic turf industry," Threshie pointed out.

Tirex anticipates announcing other TCS technology agreements currently in the discussion phase that would expand its technological reach internationally.

Simpro (http://www.simpro.it/home.php?argid=49&pagid=18〈=en), is ISO 9001 (Quality Management), ISO 14001 (Environmental Management) and EMAS (Environmental Management and Audit System) accredited. Simpro is licensed by Tirex to manufacture, install, commission and warrant turnkey TCS facilities and offer a performance bond guarantee.

The Memorandum of Understanding is subject to the approval of the boards of directors of all parties, among other things, and is subject to change. The MOU must be ratified by all parties in its final form by July 20, 2009 at a scheduled meeting to close and sign a TCS purchase agreement.

(The statements which are not historical facts contained in this news release are forward-looking statements that involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission .)

Source: The Tirex Corporation

[mick]

i saw it yesterday. what did it do today?

[WiseTrader]

Sorry ,Next one buddy!!

[learning as I go]

Nice call man, I missed it, shoulda checked the board earlier but was busy

[WiseTrader]

TXMC 0.0024- 0.0025 going on News:
Posted by: WiseTrader Date: Tuesday, July 14, 2009 12:37:45 PM
In reply to: None Post # of 168

WATCH TXMC 0.0017- 0.0018 up 38 % NEWS :


http://www.tirex-tcs.com/press.htm

[WiseTrader]

TXMC ALERT :Posted by: WiseTrader Date: Tuesday, July 14, 2009 12:37:45 PM
In reply to: None Post # of 168

WATCH TXMC 0.0017- 0.0018 up 38 % NEWS :


http://www.tirex-tcs.com/press.htm

[WiseTrader]

WATCH TXMC 0.0017- 0.0018 up 38 % NEWS :


http://www.tirex-tcs.com/press.htm

[WiseTrader]

HTDS NEWS:

Monday, July 13 2009 11:32 AM, EST Hard To Treat Diseases (HTDS.PK) Agreement With 2nd Largest Vaccine Manufacturer in China Yunnan Walvax Biotech Co PR Newswire    "US Press Releases "
SHENZHEN, China , July 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - subsidiary, Mellow Hope signed an agreement with Yunnan Walvax Biotech Co., Ltd for the Haemophilus influenza type b conjugate vaccine. Yunnan Walvax Biotech Co. Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China . This agreement / arrangement now sets the stage for Mellow Hope to be fully authorized to conduct the international marketing of Haemophilus influenza type b conjugate vaccine in the global market.

In other corporate news, the company plans on commencing the registration in Chile , Indonesia , Egypt , and Russia within this month with the brand name "MEVAC-Hib".

The company will provide further details as they become available.



Safe Harbor Statement



Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.



CONTACT: For medical and scientific dialogue inquiry only, please contact [e-mail]; For any corporate matters, please contact [e-mail], www.htdsmedical.com



SOURCE Hard to Treat Diseases

[WiseTrader]

PFMS 0.0022-0.0024

[WiseTrader]

PFMS 0.0013- 0.0014 !

[WiseTrader]

Radar's on :)

[mick]

any on top of your list for this week?

[WiseTrader]

GM everyone :)

[mick]

this one has lot of following.

[mick]

thank you very much. i have a lot to learn here.

[ive1]

GRDO check it out.

Real company https://secure.guarddogid.com/

650 million AS/OS = NO dilution
TA is ungagged and confirmed everyday.

The spokeswoman is Kendra Todd ( winner of the Apprentice).

Mediablitz is underway.

News is imminent.

0.0032 could be a steal.

Penny's soon IMO

GLTA

[WiseTrader]

great,have a nice weekend mick :)

[mick]

everyone of my forums so far no ibox.

hackers hits ihub?